Page last updated: 2024-11-06

phleomycins

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Phleomycins are a group of antitumor antibiotics produced by the bacterium Streptomyces verticillus. They are known for their potent antitumor activity against a wide range of cancer types, including leukemia, lymphoma, and solid tumors. Their unique mode of action involves the intercalation of their chromophore into DNA, leading to DNA strand scission and inhibition of DNA replication. This property makes phleomycins attractive for cancer treatment. However, their clinical use has been limited due to their severe toxicity, including nephrotoxicity and myelosuppression. Ongoing research focuses on developing phleomycin derivatives with improved therapeutic indices and reduced side effects. The phleomycin family is studied to understand its mechanism of action, to develop new anticancer drugs with better therapeutic profiles, and to explore their potential use in gene therapy and as research tools for DNA manipulation.'
```

Phleomycins: Water-soluble, copper-containing low molecular weight polypeptides obtained from the culture medium of Streptomyces verticillus. They are specific inhibitors of DNA synthesis in bacteria and have been found to act as antitumor agents. They have also been used against rust fungi of plants. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

phleomycin : A mixture of glycopeptide antibiotics originally isolated from the bacterium Streptomyces verticillus whose components all contain a thiazolinylthiazole moiety and can form complexes with redox-active metals such as Co, Cu, and Fe. (Bleomycins are very similar to phleomycins, but have a bithiazole moiety in place of the thiazolinylthiazole moiety). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID72511
SCHEMBL ID5058616
MeSH IDM0016611

Synonyms (12)

Synonym
nsc 616586
nsc 61586
nsc-61586
phleomycin
phleomycins
SCHEMBL5058616
unii-bn3e7wjn9x
J-002368
1422270-80-1
BN3E7WJN9X ,
nsc-616586
gtpl10954
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (159)

TimeframeStudies, This Drug (%)All Drugs %
pre-199054 (33.96)18.7374
1990's41 (25.79)18.2507
2000's37 (23.27)29.6817
2010's25 (15.72)24.3611
2020's2 (1.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.24 (24.57)
Research Supply Index5.13 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (2.38%)6.00%
Case Studies1 (0.60%)4.05%
Observational0 (0.00%)0.25%
Other163 (97.02%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]